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Abstract 
Pharmacogenomics is a promising new discipline that 
can realize personalized treatment for patients suffering 
from many common diseases, particularly those with 
multiple treatment modalities. Recent advances in the 
deciphering of the human genome sequence and high 
throughput genotyping technology have led to the 
reduction of the overall genotyping costs and enabled the 
inclusion of genotype-related dosing recommendations 
into drug package inserts, hence allowing the integration 
of pharmacogenomics into clinical practice. Although, 
pharmacogenomics gradually assumes an integral part in 
mainstream medical practice in developed countries, many 
countries, particularly from the developing world, still do 
not have access either to the knowledge or the resources to 
individualize drug treatment. The PharmacoGenetics for 
Every Nation Initiative (PGENI) aims to fill in this gap, by 
making pharmacogenomics globally applicable, not only 
by defining population-specific pharmacogenomic marker 
frequency profiles and formulating country-specific 
recommendations for drug efficacy and safety but also by 
increasing general public and healthcare professionals’ 
awareness over pharmacogenomics and genomic medicine. 
This article highlights the PGENI activities in Europe and 
its implementation in the Maltese population, in an effort 
to make pharmacogenomics readily applicable in European 
healthcare systems. 
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Introduction 
The genomic revolution promises to lead to better 
diagnosis of disease and selection of therapy.
1,2
 In the 
recent years, we have witnessed a significant increase in 
the amount of DNA variation data that are predictive for 
risk of toxicity or lack of effectiveness for commonly used 
treatment modalities. Pharmacogenomics can enhance the 
assessment of drug efficacy and safety to the current 
systematic process for rational drug use and may play a 
significant role in the evaluation of the overall cost-benefit 
for competing therapies.
3
 Consequently, genome-based 
therapy is gradually being introduced in developed 
countries to a greater or lesser extent and several national 
pharmacogenomic networks are being formed, e.g. in the 
United Kingdom, the Netherlands, as so on. At the same 
time, genomic information may be equally useful to other 
countries around the world to enable integration of 
medications into national formularies in a safe and 
effective manner.  
However, despite much research over the last decade, 
the clinical application of pharmacogenomics is still 
poorly integrated in the majority of the underdeveloped 
and developing countries, where genetic testing and 
pharmacogenomics may be considered as luxury items, 
since supply of electricity and fresh water is not 
guaranteed and modern healthcare infrastructure is missing. 
This, notwithstanding, does not imply that the application 
of genetics is not useful for the developing world to 
stratify public healthcare decisions. 
Availability of drugs in countries around the world is 
overseen by national health authorities, often based on 
recommendations issued by regional agencies, such as the 
European Medicines Agency (http://www.ema.europa.eu), 
or international authorities, such as the World Health 
Organization (http://www.who.int). In most cases, 
however, drug safety, efficacy and dosing information is 
based on White European-based studies that involve 
subjects from e.g. the United States, Europe or Canada and 
hence very little is known about how these drugs function 
in other populations worldwide.  
This article aims to outline the various steps that need 
to be undertaken for implementing pharmacogenomics in 
developing countries in Europe, using the Maltese 
population as an example, and the various obstacles that 
should be overcome to reach the maximum benefit in 
national healthcare systems. 
 
Pharmacogenomics and developing countries 
The PharmacoGenetics for Every Nation Initiative 
(PGENI; http://www.pgeni.org) is an international project 
aiming to incorporate pharmacogenomics into the national 
medication selection decision-making process in 
developing countries, providing improved rational drug 
selection.
2
 PGENI aims to: (a) promote the integration of 
genetic information into the public health decision-making 
process, (b) enhance the understanding of 
pharmacogenomics in developing countries, (c) 
increase awareness over pharmacogenomics and 
genomic medicine in the general public and healthcare 
professionals in developing countries, (d) provide 
guidelines for medication prioritization for developing 
countries using pharmacogenomic information, and (e) 
help to establish infrastructure for future 
pharmacogenomic research studies.
2
 
There are several drugs whose efficacy and/or 
toxicity is correlated with genomic variants, for which 
the relevant pharmacogenomic information is available 
in the drug label 
(http://www.fda.gov/drugs/scienceresearch/researchare
as/pharmacogenetics/ucm083378.htm). For example, 
HLA-B*5701 screening is highly recommended prior 
to treatment with Abacavir to prevent drug-related 
hypersensitivity reaction. The allele frequency of this 
marker is highly variable, i.e. from less than 1% in 
sub-Saharan Africa to up to 20% in India, while in 
European populations HLA-B*5701 frequency varies 
between 1% and 7% .
4
 The same is true for the allele 
frequency of many other pharmacogenomic markers, 
that are documented in dedicated repositories, such as 
the Frequency of Inherited Disorders database 
(FINDbase; http://www.findbase.org).
5,6
 The main 
PGENI study plan includes screening for the 
commonest pharmacogenomic markers in 50-500 
healthy volunteers from various populations and ethnic 
groups worldwide and the formulation of 
recommendations for genome-based prioritization of 
medication selection. Selection of participating 
countries is mainly based on the existence of a 
moderate to good healthcare system infrastructure, 
which is nevertheless insufficient to integrate 
individual patient genotyping into routine clinical 
practice. Pharmacogenomic markers include variants 
in CYP450 enzymes (e.g. CYP2D6, CYP2C9, 
CYP2C19, CYP4F2, etc), phase II enzymes (e.g. 
NAT1, NAT2, DPYD, UGT1A1, etc), drug 
transporters (e.g. MDR1, ABCC1, SLCO1A1, etc), 
transcription regulators and other enzymes that have 
been shown to be relevant to drug metabolism (e.g. 
RXRA, AHR, PPARD, PPARG, etc.).
7
 The PGENI 
project is coordinated by the Institute of 
Pharmacogenomics and Individualized Therapy of the 
University of North Carolina (Chapel Hill, NC, USA) 
and 8 Regional Centers in the Americas (Mexico, 
Brazil), Africa (Ghana, South Africa), Asia (China, 
Jordan, India) and Europe (Greece). These entities are 
established Centers of Excellence to promote 
pharmacogenomics education and research, integrate 
pharmacogenomics into healthcare professional 
education that would potentially serve as a resource to 
the respective Ministries of Health. Also, these 
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regional centers will be responsible to advance the 
research capabilities in developing nations with regional 
experts, so that the necessary research infrastructure for 
advancing pharmacogenomics research in these 
populations is established. Ultimately, the population- and 
ethnic group-specific pharmacogenomic marker allele 
frequency information will assist the development of 
country- and population-specific national 
recommendations for various therapeutic modalities.
8 
 
 
Pharmacogenomics in Europe: challenges and pitfalls 
The extent of implementation of pharmacogenomics in 
the various European healthcare systems may be hindered 
by several factors. First of all, not all European countries 
are European Union (EU) member-states, indicating that 
they are not subject to EU guidelines and directives, e.g. 
European Medicines Agency recommendations. Also, 
even among the 27 EU member states, the implementation 
of the various EU directives, particularly related to 
healthcare and education, is not uniform and relies on the 
national legislation. Furthermore, even though certain 
countries belong to the EU, they are likely to resemble 
more (e.g. culturally, religiously) with others that are not 
EU member states. Last, but not least, the Eurozone 
member states differ substantially in fiscal terms, which 
directly impacts the available healthcare and national 
insurance spending. These factors make the 
implementation of pharmacogenomics in developing 
European countries an even more challenging task. 
 The European Regional center of the PGENI initiative 
is the Golden Helix Institute of Biomedical Research 
(http://www.goldenhelix.org)
9
, an international non-profit 
scientific organization with interdisciplinary research and 
educational activities in the field of genome medicine. 
Briefly, the PGENI-related activities of the Golden Helix 
Institute of Biomedical Research are: 
a) Coordination of sample collection from healthy 
volunteers originating from various developing 
European countries that participate in the PGENI 
project. So far, DNA samples from over 20 
European countries have been collected and 
processed 
(http://www.goldenhelix.org/index.php/research/the
-pgeni-project). 
b) Documentation of the pharmacogenomic markers 
allele frequencies in the FINDbase database 
(http://www.findbase.org),
5,6
 as part of the Golden 
Helix Server. 
c) Organization of education activities in the PGENI 
European countries to disseminate information 
pertaining to pharmacogenomics to achieve 
knowledge transfer to society. These educational 
activities, known as the Golden Helix 
Pharmacogenomics days 
(http://www.goldenhelixsymposia.org)
10,11
 are 
organized in major cities with large academic 
hospitals, aiming to (i) provide timely updates 
on the field of pharmacogenomics and 
personalized medicine to the local biomedical 
scientists and healthcare professionals, (ii) 
increase awareness over pharmacogenomics 
and their application in various areas of 
medical practice, and (iii) network faculty 
members from universities and research 
institutes from the local scientific arena 
working in the field of pharmacogenomics in 
order to initiate collaborative projects in this 
field.  
d) Evaluation and critical assessment of the 
pharmacogenomic environment in PGENI 
European countries, particularly pertaining to 
genetic laboratories, the general public and 
healthcare professionals.  
e) Establishment of guidelines and 
recommendations for integrating 
pharmacogenomics in developing countries’ 
healthcare systems (Table 1).  
 
Establish national networks of clinicians and 
researchers involved in pharmacogenomics in 
developing countries.  
Encourage communication and research interactions 
with healthcare systems and pharmacogenomics 
networks in developed countries. 
Create international networks between (closely 
related) developing countries to enhance 
communication, interaction, pursue funding and 
initiate joint research projects. 
Develop a framework to catalyze knowledge transfer 
between the regional centre, national healthcare 
authorities and international agencies. 
Ensure that all legal, ethical, social and religious 
issues are thoroughly addressed.   
Table 1. Proposed recommendations for integrating 
pharmacogenomics in developing countries’ healthcare 
systems. 
 
Considering the fact that genome-based 
rationalization of drug treatment can contribute 
towards the reduction of the National Healthcare 
spending, mostly by reducing hospitalization due to 
the various adverse drug reactions, this need is more 
than ever urgent, particularly in South European 
countries who have a vast fiscal deficit. In Germany, 
adverse drug reactions cause the death, hospitalization, 
or serious injury of over 2 million people each year, of 
which up to 30% of cases are preventable. Direct 
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treatment costs of adverse drug reaction in internal 
medicine total €434 million annually; base models 
including all medical specialties have extrapolated this 
figure to be more than €816 million.8,12,13 
These activities contribute to the generation of new 
knowledge and its dissemination to the various 
stakeholders, which address, in part or fully, several of the 
issues that are currently considered as hurdles that hold 
this field back, such as, healthcare costs, education of 
healthcare professionals, proper regulation of 
(pharmaco)genomic tests, data collection, storage and 
retrieval.
14 
 
 
Implementation of pharmacogenomics in Malta 
 Malta joined the PGENI project in July 2011 and, 
together with Greece, Serbia and Poland, was among the 
first countries to express their interest to participate in this 
multinational initiative. The PGENI project in Malta is 
overseen by Drs. Fenech, Grech and Borg from the 
University of Malta. During Phase I of the project, 45 
DNA samples from healthy volunteers were analyzed 
during the DMET+ platform (Affymetrix, Santa Clara, CA, 
USA). Principal component analysis indicates that the 
Maltese population nicely clusters together with the 
Caucasian population, as expected (Figure 1). However, 
for several pharmacogenomic markers, the allele 
frequencies in the Maltese population are significantly 
different compared to those observed in the Caucasian 
population. For example, the allele frequencies observed 
for several CYP2D6 alleles in the Maltese population are 
different compared to those observed in the Caucasian 
population, while although the TPMT*3C allele frequency 
is 3% in the Caucasian population, this allele is completely 
absent in the Maltese population (data not shown). These 
findings warrant further investigation during the Phase II 
of the project that will soon commence.  
 
 
Figure 1. Principal component analysis, depicting that the 
Maltese population nicely clusters with the Caucasian 
population. 
 
Also, consistent with the efforts of increasing 
awareness over pharmacogenomics in the healthcare 
professionals and Bioscientists in the Maltese 
population, a Golden Helix Pharmacogenomics Day 
was organized on December 3
rd
, 2011, in the 
University of Malta in Msida, by the Golden Helix 
Institute of Biomedical Research and the Faculty of 
Medicine and Surgery, University of Malta. This event 
was supported by the Foundation of Medical Sciences, 
Affymetrix, Illumina, QIAGEN, and the 
Mediterranean bank and was attended by over 160 
registered participants. The lectures from the European 
Commissioner for Health and Consumer Policy John 
Dalli, Professor Marisa Papaluca-Amati from the 
European Medicines Agency, Professor Ron van 
Schaik from Erasmus MC in Rotterdam, the 
Netherlands and several other leading scientists further 
emphasized the impact of this event towards informing 
the healthcare professionals over the importance of 
pharmacogenomics.
10
 
These are some of the PGENI-related activities, 
which will undoubtedly positively impact on the 
pharmacogenomics community in Malta.    
 
Conclusions 
As more pharmacogenomic information becomes 
available from data collection and analysis from the 
various PGENI countries in Europe, this will not only 
accelerate the integration of pharmacogenomics in 
healthcare decision-making at the country level but 
will also support new pharmacogenomics research 
initiatives in areas with low research potential. Also, 
targeted educational efforts will also prepare the 
Ministry of Health staff from participating countries to 
better integrate genetic information into many areas of 
healthcare, including disease management and 
therapeutic interventions.  
Overall, individualization of drug therapy is the 
ultimate goal, providing the rationale for implementing 
pharmacogenomics in healthcare provision in 
developing countries in Europe and worldwide. 
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